drugset / Trial / NCT05447260

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

NCT05447260

Phase 4 Unknown 87 enrolled Qilu Hospital of Shandong University
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

Timeline

Start
2022-06-10
Primary completion
2022-12-10
Completion
2023-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule

Indications